A new study suggests Paxlovid may not reduce risk of covid hospitalizations and all-cause deaths in vaccinated adults ages 65 to 74. Paxlovid, the five-day antiviral treatment for covid, may not reduce the risk of covid-related hospitalizations and all-cause deaths in vaccinated older adults, a new study suggests.
Paxlovid — Pfizer’s combination of nirmatrelvir and ritonavir — has been found to reduce symptoms, hospitalizations and deaths in unvaccinated, at-risk patients. However, a Pfizer trial published in 2024 found the medication didn’t significantly shorten the duration of symptoms in vaccinated adults.